Study on LARS2: Drug Targets and Biomarkers (G23395)

Target Name: LARS2

NCBI ID: G23395

LARS2

Study on LARS2: Drug Targets and Biomarkers

LARS2 (leucine-rich repeat-containing 2) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is characterized by the presence of a unique repeat sequence, known as a leucine -rich repeat, which is composed of the amino acids leucine, isoleucine, and valine.

The study of LARS2 has identified a number of potential drug targets and biomarkers. One of the main focuses of research into LARS2 has been its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Recent studies have shown that LARS2 is involved in the formation of neurofibrillary tangles, which are thought to contribute to the neurofibrillary tangles that are present in the brains of individuals with Alzheimer's disease. Additionally, LARS2 has been shown to be involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of neurodegenerative diseases.

Another potential drug target for LARS2 is its role in the regulation of cellular signaling pathways. LARS2 has been shown to be involved in the regulation of several signaling pathways, including the TGF-β pathway and the Wnt pathway. These pathways are involved in the development and maintenance of tissues and organs, and are thought to be involved in the development of a number of diseases, including cancer.

In addition to its potential as a drug target, LARS2 has also been shown to be a potential biomarker for a number of diseases. For example, LARS2 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and has been used as a biomarker for this disease in animal models. Additionally, LARS2 has been shown to be involved in the development of neurofibrillary tangles in the brains of individuals with Parkinson's disease, and has been used as a biomarker for this disease in animal models.

Overall, the study of LARS2 has identified a number of potential drug targets and biomarkers, and has the potential to contribute to the development of new treatments for a number of neurodegenerative diseases. Further research is needed to fully understand the role of LARS2 in these diseases and to develop effective treatments.

Protein Name: Leucyl-tRNA Synthetase 2, Mitochondrial

Functions: Catalyzes the attachment of leucine to its cognate tRNA

The "LARS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LARS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets